- Reuters•9 hours ago
Medtronic Plc won U.S. approval on Wednesday for an "artificial pancreas" that is the first device to automatically deliver the right dose of insulin to patients with type 1 diabetes, freeing them from continually monitoring insulin levels throughout each day. The U.S. Food and Drug Administration, in its approval of the device, the MiniMed 670G, hailed it as a breakthrough. The device offers type 1 diabetics "greater freedom to live their lives without having to consistently and manually monitor baseline glucose levels and administer insulin," Dr. Jeffrey Shuren, director of the FDA's medical device division, said in a statement.
- Business Wire•2 days agoDexCom Schedules Third Quarter 2016 Earnings Release and Conference Call for November 1, 2016 at 4:30 p.m. Eastern Time
DexCom, Inc. today announced that it plans to release its third quarter 2016 financial results after market close on Tuesday, November 1, 2016. Management will hold a conference call to review the company's third quarter 2016 performance starting at 4:30 p.m.
- Capital Cube•7 days ago
Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to DexCom, Inc. Here are 5 ETF’s with the largest exposure to DXCM-US. Comparing the performance and risk of DexCom, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
DexCom, Inc. (DXCM)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||60.12 x 100|
|Day's Range||84.72 - 93.72|
|52wk Range||47.92 - 96.38|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-91.48|
|Avg Vol (3m)||826,509|
|Dividend & Yield||N/A (N/A)|